FDC Limited
NSE: FDCMarket Closed • NSE
Day range
52 week range
FDC Limited closed at INR356.25 (+1.38%) on volume 0.76x its 20-day average, trading 24.78% below its 52-week high.
2026-Q1
Q1 FY2026 Financial Results
PAT moved +265.3% QoQ
2026-02-11
DIVIDEND Announced
Interim Dividend - Rs 5 Per Share
2024-11-22
DIVIDEND Announced
Interim Dividend - Rs 5 Per Share
Revenue and PAT bars use independent scales to make their year-on-year direction readable.
Complete reported financial history · Values use the company's reporting currency
Hover over the chart for exact reported values. Percentage lines use the right-hand axis.
A 0–100 quantitative summary of reported fundamentals. Use the underlying financials and risks for context; the score is not a buy or sell recommendation.
Strengths
Attractive Valuation: P/E of 19.8x trades below sector historical averages
Risks
Subject to cyclical raw material and macro industry pressures
Bull case
Market Leadership: Established operational scale in Drug Manufacturers - Specialty & Generic.
Bear case
Macro Headwinds: Fluctuations in interest rates and sector-specific policy shifts could compress multiples.
Flip condition
Sustained quarterly EBITDA margin expansion above 20% would trigger an upgrade.
Complete dividend, bonus, split, rights and other action history
| Record date | Corporate action | Information | Announcement date | Ex-date |
|---|---|---|---|---|
| 11 Feb 2026 | Dividend | ₹5.00 / share | — | 11 Feb 2026 |
| 22 Nov 2024 | Dividend | ₹5.00 / share | — | 22 Nov 2024 |
| — | Annual General Meeting | Annual General Meeting | — | 19 Sept 2024 |
| — | Annual General Meeting | Annual General Meeting | — | 20 Sept 2023 |
| 25 Aug 2023 | Buy Back | Buy Back | — | 25 Aug 2023 |
| — | Annual General Meeting | Annual General Meeting | — | 13 Sept 2022 |
| 19 Feb 2022 | Buy Back | Buy Back | — | 17 Feb 2022 |
| — | Annual General Meeting | Annual General Meeting | — | 20 Sept 2021 |
| — | Annual General Meeting | Annual General Meeting | — | 22 Sept 2020 |
| 21 Aug 2020 | Buyback | Buyback | — | 20 Aug 2020 |
| 21 Mar 2020 | Dividend | ₹0.80 / share | — | 19 Mar 2020 |
| — | Annual General Meeting | Annual General Meeting | — | 19 Sept 2019 |
| 07 Jun 2019 | Buyback | Buyback | — | 06 Jun 2019 |
| — | Annual General Meeting | Annual General Meeting | — | 30 Aug 2018 |
| 27 Feb 2018 | Buyback | Buyback | — | 26 Feb 2018 |
| — | Dividend | ₹2.25 / share | — | 08 Aug 2017 |
| — | Annual General Meeting | Annual General Meeting | — | 06 Sept 2016 |
| 19 Mar 2016 | Dividend | ₹2.25 / share | — | 17 Mar 2016 |
| — | Dividend | ₹2.25 / share | — | 23 Sept 2015 |
Traded volume and delivery percentage across the latest 20 sessions
Compare valuation, latest quarterly performance and year-on-year growth
| Company name | Market cap ₹ Cr | P/E ratio | Dividend yield % | Quarterly sales ₹ Cr | Profit after tax ₹ Cr | Sales growth % | Profit growth % |
|---|---|---|---|---|---|---|---|
 Sun Pharmaceutical Industries LimitedSUNPHARMA Open analysis | ₹4.22L | 34.90 | 0.91% | ₹15,300.00 | ₹2,901.00 | +10.46% | +26.52% |
 Divi's Laboratories LimitedDIVISLAB Open analysis | ₹2.43L | 82.97 | 0.33% | ₹3,080.00 | ₹902.00 | +27.80% | +65.50% |
 Torrent Pharmaceuticals LimitedTORNTPHARM Open analysis | ₹1.73L | 72.83 | 0.83% | ₹4,128.00 | ₹389.00 | +41.90% | -21.89% |
 Apollo Hospitals Enterprise LimitedAPOLLOHOSP Open analysis | ₹1.13L | 54.32 | 0.25% | ₹7,044.00 | ₹610.00 | +20.58% | +38.32% |
 Zydus Lifesciences LimitedZYDUSLIFE Open analysis | ₹1.12L | 25.03 | 0.09% | ₹8,017.00 | ₹990.00 | +21.95% | -34.91% |
 LENSKART SOLUTIONS LTDLENSKART Open analysis | ₹1.12L | 174.73 | 0.00% | ₹2,714.00 | ₹228.00 | +43.29% | +273.77% |
 Laurus Labs LimitedLAURUSLABS Open analysis | ₹1.11L | 101.83 | 0.12% | ₹2,026.31 | ₹367.60 | +29.10% | +125.49% |
 Cipla LimitedCIPLA Open analysis | ₹1.07L | 31.78 | 0.98% | ₹7,119.00 | ₹786.00 | +2.33% | -39.16% |
FDC Limited, together with its subsidiaries, manufactures and trades in pharmaceutical products in India, the United States, and internationally. The company offers pharmaceutical formulations for various therapeutic segments, including anti-infectives, gastrointestinal, ophthalmology, vitamins, minerals, dietary supplements, cardiovascular and anti-diabetic therapies, respiratory care, gynaecology, dermatology, and analgesics in the form of tablets, capsules, oral liquids, ophthalmic drops, topical preparations, and paediatric-friendly solutions. It also provides functional food, such as flavoured ORS powders, ready-to-drink electrolyte beverages, vitamin-enriched supplements, antioxidant blends and protein-fortified drinks; and various active pharmaceutical ingredients. The company sells its products under the Zifi, Zefu, Zocon, Amodep-AT, Zathrin, Vitcofol, Ziglim, Ziglim-M,Mycoderm, Zoxan, Cotaryl, Pyrimon DF, Zipod, Electral, and Enerzal brands. It also exports its products to approximately 50 countries. FDC Limited was founded in 1936 and is based in Mumbai, India.
IndiaHealthcare
Is FDC Limited Shariah compliant?
FDC Limited is currently screened as Shariah Compliant under AAOIFI Shariah Standard No. 21. Business activities align with Shariah permissible sectors. Debt to Market Cap (0.27%) complies with AAOIFI threshold (≤ 33%).
What is FDC Limited's current valuation relative to peers?
FDC Limited trades at a P/E of 19.8x compared to the sector median of 37x, and a Price-to-Book of 2.3x.
Is the company financially healthy?
The company has a Debt-to-Equity ratio of 0.62x. Interest coverage is 57.5x.
What are the historical revenue and profit growth rates?
Over the past 5 years, revenue compounded at 10.2% while net profit growth averaged -1.4%.
Market data is informational and may be delayed. Shariah screening follows the displayed methodology. This is not investment advice.
Market data may be delayed. Quote date: 2026-10-16. Financial figures relate to their stated reporting periods. This information is for research and is not a recommendation to buy or sell.